Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Fig. 4

Overall survival (OS) (a) and leukaemia-free survival (LFS) (b) by cytogenetics subgroup. Mono5 refers as the presence of monosomy 5 or loss of 5q and mono7 refers as the presence of monosomy 7. Absence of Mono5 was associated to a better OS (2-year OS 47% [95% CI 30–65] and 31% [95% CI 0–63] in patients without and with mono7, respectively) compared to the subset of patients harbouring mono5 (2-year OS: 16% [95% CI 1–31] and 10% [95% CI 0–22], according to simultaneous mono7 or not, respectively) (a). The deleterious impact of mono5 on LFS was independent of presence of additional mono7, with a 2-year LFS of 11% [95% CI 0–23] (mono5 without mono7) and 13% [95% CI 0–27] (mono5 with mono7) vs 38% [95% CI 9–67] (absence of mono5 with mono7) and 37% [95% CI 20–53] (absence of both abnormalities, p = 0.007) (b)

Back to article page